BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update
Conference Call scheduled on May 7, 2019 at 8:30 AM EDT
NEW HAVEN, Conn., April 29, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology, today announced that it plans to release its financial results for the first quarter 2019 ended March 31, 2019 on Tuesday, May 7, 2019. BTI plans to hold a conference call at 8:30 AM Eastern Time on Tuesday, May 7, 2019 to discuss the financial results and provide a business update.
| CONFERENCE CALL & WEBCAST | ||
| Tuesday, May 7, 2019, 8:30 AM Eastern Time | ||
| Domestic: | 1-888-394-8218 | |
| International: | 1-323-794-2588 | |
| Conference ID: | 9482739 | |
| Webcast: | http://public.viavid.com/index.php?id=134360 | |
| Replay – Available through June 7, 2019 | ||
| Domestic: | 1-844-512-2921 | |
| International: | 1-412-317-6671 | |
| Conference ID: | 9482739 | |
About BioXcel Therapeutics, Inc. (BTI):
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
The Ruth Group for BTI:
Lee Roth / Janhavi Mohite
646-536-7012 / 7026
lroth@theruthgroup.com / jmohite@theruthgroup.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
